| Product NDC: | 63739-450 |
| Proprietary Name: | buPROPion Hydrochloride |
| Non Proprietary Name: | buPROPion Hydrochloride |
| Active Ingredient(s): | 150 mg/1 & nbsp; buPROPion Hydrochloride |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 63739-450 |
| Labeler Name: | McKesson Packaging Services Business Unit of McKesson Corporation |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA077285 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 20110221 |
| Package NDC: | 63739-450-10 |
| Package Description: | 10 BLISTER PACK in 1 BOX, UNIT-DOSE (63739-450-10) > 10 TABLET in 1 BLISTER PACK |
| NDC Code | 63739-450-10 |
| Proprietary Name | buPROPion Hydrochloride |
| Package Description | 10 BLISTER PACK in 1 BOX, UNIT-DOSE (63739-450-10) > 10 TABLET in 1 BLISTER PACK |
| Product NDC | 63739-450 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | buPROPion Hydrochloride |
| Dosage Form Name | TABLET |
| Route Name | ORAL |
| Start Marketing Date | 20110221 |
| Marketing Category Name | ANDA |
| Labeler Name | McKesson Packaging Services Business Unit of McKesson Corporation |
| Substance Name | BUPROPION HYDROCHLORIDE |
| Strength Number | 150 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Aminoketone [EPC],Dopamine Uptake Inhibitors [MoA],Increased Dopamine Activity [PE],Increased Norepinephrine Activity [PE],Norepinephrine Uptake Inhibitors [MoA] |